Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

The effect of using pazopanib with food vs fasted on pharmacokinetics, patient safety and preference (DIET study).

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Clin Pharmacol Ther. 2019 May 24. doi: 10.1002/cpt.1515. [Epub ahead of print]

PMID:
31125423
2.

Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs utilizing therapeutic drug monitoring data in children living with HIV.

Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, Burger DM.

Ther Drug Monit. 2019 Apr 16. doi: 10.1097/FTD.0000000000000637. [Epub ahead of print]

PMID:
31008997
3.

Importance of prospective studies in pregnant and breastfeeding women living with HIV.

Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D.

Clin Infect Dis. 2019 Feb 13. pii: ciz121. doi: 10.1093/cid/ciz121. [Epub ahead of print]

PMID:
30783649
4.

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.

Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.

J Antimicrob Chemother. 2019 Jan 30. doi: 10.1093/jac/dky567. [Epub ahead of print]

PMID:
30715324
5.

Protein binding of rifampicin is not saturated when using high-dose rifampicin.

Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team .

J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527.

PMID:
30597025
6.

Efavirenz pharmacokinetics during pregnancy and infant washout.

Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D.

Antivir Ther. 2019;24(2):95-103. doi: 10.3851/IMP3283.

PMID:
30530925
7.

Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.

van Seyen M, Smolders EJ, van Wijngaarden P, Drenth JPH, Wouthuyzen-Bakker M, de Knegt RJ, Honkoop P, El-Sherif O, Colbers A, Back DJ, Burger DM.

J Hepatol. 2019 Mar;70(3):552-554. doi: 10.1016/j.jhep.2018.10.010. Epub 2018 Nov 23. No abstract available.

PMID:
30473264
8.

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.

Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, Achmad TH, Colbers A, Te Brake L, van Crevel R, Ruslami R, Aarnoutse R.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01014-18. doi: 10.1128/AAC.01014-18. Print 2018 Dec.

9.

First reported use of zidovudine for prevention of perinatal HIV transmission in a premature neonate on extra corporal membrane oxygenation.

Emonts M, Waalewijn H, Colbers A, Pickering A, Burger D.

AIDS. 2018 Sep 10;32(14):2084-2085. doi: 10.1097/QAD.0000000000001940. No abstract available.

PMID:
30157085
10.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
11.

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

van der Galiën R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM.

Clin Pharmacokinet. 2019 Mar;58(3):309-323. doi: 10.1007/s40262-018-0684-z. Review.

12.

Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.

Roskam-Kwint M, Bollen P, Colbers A, Duisenberg-van Essenberg M, Harbers V, Burger D.

J Antimicrob Chemother. 2018 Sep 1;73(9):2430-2434. doi: 10.1093/jac/dky191.

PMID:
29796595
13.

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.

Knapen LM, Koornstra RHT, Driessen JHM, van Vlijmen B, Croes S, Schalkwijk S, Colbers A, Gerritsen WR, Burger DM, de Vries F, van Erp NP.

Target Oncol. 2018 Jun;13(3):363-370. doi: 10.1007/s11523-018-0564-3.

14.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

15.

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.

Bastiaans DET, Geelen SPM, Visser EG, van der Flier M, Vermont CL, Colbers APH, Roukens M, Burger DM, van Rossum AMC; Dutch Paediatric HIV Study Group.

Pediatr Infect Dis J. 2018 Oct;37(10):1008-1010. doi: 10.1097/INF.0000000000001964.

PMID:
29474261
16.

Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics.

Smolders EJ, Thammajaruk N, de Kanter CTMM, Colbers A, Chaiyahong P, Cuprasitrut T, Chittmittraprap S, Apornpong T, Khemnark S, Tangkijvanich P, Burger DM, Avihingsanon A.

Trop Med Int Health. 2018 Mar;23(3):295-305. doi: 10.1111/tmi.13027. Epub 2018 Jan 10.

17.

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.

Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study.

Antivir Ther. 2018;23(3):259-265. doi: 10.3851/IMP3198.

PMID:
28994660
18.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

19.

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.

Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, Russel FGM.

Clin Pharmacokinet. 2018 Jun;57(6):705-716. doi: 10.1007/s40262-017-0583-8.

20.

Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?

Lubberman FJE, Gelderblom H, Wilmer CM, Kweekel DM, Desar IME, Colbers A, Burger D, van der Graaf WTA, van Erp N.

Br J Clin Pharmacol. 2017 Oct;83(10):2312-2314. doi: 10.1111/bcp.13333. Epub 2017 Jul 4. No abstract available.

21.

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.

Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, Moltó J, Burger D; Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network.

Clin Infect Dis. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534.

PMID:
28595298
22.

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM.

Br J Clin Pharmacol. 2017 Oct;83(10):2225-2234. doi: 10.1111/bcp.13323. Epub 2017 Jun 6.

23.

Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.

Jongbloed-de Hoon M, Colbers A, Velthoven-Graafland K, Duisenberg-van Essenberg M, Kruijssen M, Abbink E, van Crevel R, Burger D.

J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):571-574. doi: 10.1097/QAI.0000000000001296.

PMID:
28166190
24.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

25.

Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.

Brüggemann RJ, Middel-Baars V, de Lange DW, Colbers A, Girbes AR, Pickkers P, Swart EL.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01894-16. doi: 10.1128/AAC.01894-16. Print 2017 Feb.

26.

Dolutegravir in breast milk and maternal and infant plasma during breastfeeding.

Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D.

AIDS. 2016 Nov 13;30(17):2731-2733. No abstract available.

PMID:
27782968
27.

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D.

Front Pharmacol. 2016 Aug 4;7:239. doi: 10.3389/fphar.2016.00239. eCollection 2016.

28.

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ.

J Clin Pharmacol. 2017 Feb;57(2):235-246. doi: 10.1002/jcph.798. Epub 2016 Aug 23.

PMID:
27432796
29.

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.

Schalkwijk S, Feiterna-Sperling C, Weizsäcker K, Colbers A, Bührer C, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Jul 31;30(12):1999-2001. doi: 10.1097/QAD.0000000000001123. No abstract available.

PMID:
27428578
30.

A new paediatric formulation of valaciclovir: development and bioequivalence assessment.

Bastiaans DE, Bartels-Wilmer CM, Colbers AP, Heijens CA, Velthoven-Graafland K, Smeets OS, Vink N, Harbers VE, Warris A, Burger DM.

Arch Dis Child. 2016 Oct;101(10):971-2. doi: 10.1136/archdischild-2015-310266. Epub 2016 May 9. No abstract available.

PMID:
27162003
31.

The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.

El Messaoudi S, Russel FG, Colbers A, Bandell CC, van den Broek PH, Burger DM, Rongen GA, Riksen NP.

Eur J Clin Pharmacol. 2016 Jun;72(6):725-30. doi: 10.1007/s00228-016-2039-8. Epub 2016 Mar 15.

32.

First reported use of elvitegravir and cobicistat during pregnancy.

Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Mar 13;30(5):807-8. doi: 10.1097/QAD.0000000000000976. No abstract available.

PMID:
26913711
33.

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.

Schalkwijk S, Colbers A, Konopnicki D, Weizsäcker K, Moltó J, Tenorio CH, Hawkins D, Taylor G, Wood C, van der Ende M, Burger D; PANNA network.

AIDS. 2016 May 15;30(8):1239-44. doi: 10.1097/QAD.0000000000001046.

PMID:
26836789
34.

Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.

Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VG, van Drongelen J, Teulen M, van den Oetelaar D, Burger DM, Russel FG.

J Antimicrob Chemother. 2016 Feb;71(2):480-3. doi: 10.1093/jac/dkv358. Epub 2015 Nov 3.

PMID:
26538508
35.

Pharmacokinetic drug-drug interaction study between raltegravir and citalopram.

Blonk MI, Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM.

Antivir Ther. 2016;21(2):143-52. doi: 10.3851/IMP2993. Epub 2015 Sep 16.

PMID:
26375942
36.

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

Colbers A, Greupink R, Litjens C, Burger D, Russel FG.

Clin Pharmacokinet. 2016 Mar;55(3):381-96. doi: 10.1007/s40262-015-0325-8.

37.

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.

Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team.

Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22.

38.

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.

Welzen ME, Dezentjé VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW.

Ther Drug Monit. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195.

PMID:
26192892
39.

Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.

Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, Verweij PE, Pickkers P, Brüggemann RJ.

Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9. doi: 10.1128/AAC.00623-15. Epub 2015 May 11.

40.

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsäcker K, Haberl AE, Moltó J, Hawkins DA, van der Ende ME, Gingelmaier A, Taylor GP, Ivanovic J, Giaquinto C, Burger DM; Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network.

Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5.

PMID:
25944344
41.

Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers.

Blonk M, van Beek M, Colbers A, Schouwenberg B, Burger D.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):44-51. doi: 10.1097/QAI.0000000000000544.

PMID:
25942458
42.

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.

Ahmed AI, van den Elsen GA, Colbers A, Kramers C, Burger DM, van der Marck MA, Olde Rikkert MG.

Psychopharmacology (Berl). 2015 Jul;232(14):2587-95. doi: 10.1007/s00213-015-3889-y. Epub 2015 Mar 11.

43.

The ARRIBA concept: adequate resorption of ribavirin.

de Kanter CT, Koning L, Berden FA, Wasmuth JC, Grintjes-Huisman KJ, Becker B, Colbers AP, Roukens MM, Rockstroh JK, Drenth JP, de Knegt RJ, Dofferhoff AS, Burger DM.

Antivir Ther. 2015;20(5):515-20. doi: 10.3851/IMP2935. Epub 2015 Jan 19.

PMID:
25599333
44.

A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.

Brüggemann RJ, Van Der Velden WJ, Knibbe CA, Colbers A, Hol S, Burger DM, Donnelly JP, Blijlevens NM.

J Antimicrob Chemother. 2015 Apr;70(4):1166-74. doi: 10.1093/jac/dku477. Epub 2014 Dec 3.

PMID:
25473029
45.

Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.

Kerr SJ, Punyawudho B, Thammajaruk N, Colbers A, Chaiyahong P, Phonphithak S, Sapsirisavat V, Ruxrungtham K, Burger DM, Avihingsanon A.

AIDS Res Hum Retroviruses. 2015 Apr;31(4):368-74. doi: 10.1089/AID.2014.0249. Epub 2014 Dec 17.

PMID:
25384393
46.

Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.

Colbers A, Moltó J, Ivanovic J, Kabeya K, Hawkins D, Gingelmaier A, Taylor G, Weizsäcker K, Sadiq ST, Van der Ende M, Giaquinto C, Burger D; PANNA Network.

J Antimicrob Chemother. 2015 Feb;70(2):534-42. doi: 10.1093/jac/dku400. Epub 2014 Oct 17.

PMID:
25326090
47.

Pharmacokinetics of caspofungin in ICU patients.

Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A, Verweij PE, Burger DM, Pickkers P, Brüggemann RJ.

J Antimicrob Chemother. 2014 Dec;69(12):3294-9. doi: 10.1093/jac/dku313. Epub 2014 Aug 19.

PMID:
25139840
48.

Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial.

Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1475-82. doi: 10.1016/j.euroneuro.2014.06.007. Epub 2014 Jun 28.

PMID:
25035121
49.

Atazanavir exposure is effective during pregnancy regardless of tenofovir use.

Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Gingelmaier A, Weizsäcker K, Kabeya K, Taylor G, Rockstroh J, Lambert J, Moltó J, Wyen C, Sadiq ST, Ivanovic J, Giaquinto C, Burger D; PANNA network.

Antivir Ther. 2015;20(1):57-64. doi: 10.3851/IMP2820. Epub 2014 Jul 3.

PMID:
24992294
50.

Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.

Jacobs BS, Colbers AP, Velthoven-Graafland K, Schouwenberg BJ, Burger DM.

Int J Antimicrob Agents. 2014 Aug;44(2):173-7. doi: 10.1016/j.ijantimicag.2014.03.014. Epub 2014 May 23.

PMID:
24929949

Supplemental Content

Loading ...
Support Center